Researchers have identified the origin of ovarian cancer that develops in the fallopian tube, which opens doors to ...

Tumours shrank or stopped growing in almost one in three women (31 per cent) with low-grade serous ovarian cancer, which does ...

Almost a third (31%) of women with low-grade serous ovarian cancer, which does not respond well to chemotherapy, saw their ...

Scientists say the Royal Marsden hospitals' drug trial could change practice globally for serous form of ovarian cancer which ...

A groundbreaking study has uncovered the origin of one of the most aggressive forms of ovarian cancer, called high-grade ...

The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is ...

The cell of origin for high-grade serous carcinoma (HGSC) remains to be determined. Here, the authors characterize the different cell types and states of the mouse uterine tube and identify ...

Pembrolizumab plus concurrent chemoradiotherapy demonstrated a higher progression-free survival rate than placebo plus concurrent chemoradiotherapy for patients with ...

Scientists have been awarded funding to create the world’s first ovarian cancer vaccine. OvarianVax, is a vaccine that will teach the immune system to recognise and attack the earliest stages of ...